| Trial ID: | L6413 |
| Source ID: | NCT01035528
|
| Associated Drug: |
Insulin Glargine
|
| Title: |
Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Coronary Artery Disease|Type 2 Diabetes
|
| Interventions: |
DRUG: insulin glargine|DRUG: metformin
|
| Outcome Measures: |
Primary: change from baseline to endpoint in myocardial diastolic velocity E', 24 weeks | Secondary: glucose control, 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: Munich Municipal Hospital | Collaborators: Aventis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
32
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2005-04
|
| Completion Date: |
2010-08
|
| Results First Posted: |
|
| Last Update Posted: |
2009-12-18
|
| Locations: |
Staedt. Klinikum Muenchen Bogenhausen, Munich, Bavaria, 81925, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT01035528
|
